Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 placebo-controlled single-blind study of subcutaneous ALN-GO1 in healthy adults and patients with primary hyperoxaluria type 1
MOH_2017-05-28_000392Phase 2Not yet recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) (4 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoints: Safety, Tolerability and 2 more. Planned start Jun 2016; status: not yet recruiting.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on MOH_2017-05-28_000392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-28_000392.